Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
C
Cao, Brad
UMB
PII-072
-
LEVERAGING SUPERVISED MACHINE LEARNING TO IDENTIFY PREDICTORS OF ADVERSE EVENTS WITH STIMULANT TREATMENT FROM REAL-WORLD DATA
Brad Cao
Favorite
Chaba, Linda
UCSF
PI-006
-
OPTIMIZING REGIMEN COMBINATIONS FOR TUBERCULOSIS DRUG DEVELOPMENT.
Linda Chaba
Favorite
Chan, Rosa
Longboard Pharmaceuticals
PI-063
-
DISPOSITION OF BEXICASERIN TO ITS MAJOR METABOLITE, N-CARBAMOYL GLUCURONIDE (M20), IS NOT INFLUENCED BY GENETIC POLYMORPHIC METABOLISM
Rosa Chan
Favorite
Chen Gan, Jia Wen
UC San Diego
PII-119
-
EVALUATING AND OPTIMIZING ALLOMETRIC SCALING APPROACHES FOR PREDICTING PEDIATRIC EXPOSURES OF INTRAVENOUSLY ADMINISTERED SMALL MOLECULES AND BIOLOGICS FROM ADULT DATA
Jia Wen Chen Gan
Favorite
Chenchula, Santenna
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, Bhopal
PI-045
-
FREQUENCIES OF CLINICALLY ACTIONABLE POLYMORPHISMS, GENOTYPES, AND PHENOTYPES OF CYP2D6 AND CYP2C19 GENES IN THE CENTRAL INDIAN POPULATION WITH COMMON MENTAL DISORDERS
Santenna Chenchula
Favorite
Cheng, Limei
Incyte Corporation
PII-053
-
A NOVEL MODELING APPROACH FOR PREDICTING THE TIME COURSE OF ANTI-DRUG ANTIBODIES OF BIOLOGICS: APPLICATION TO AXATILIMAB AS AN EXAMPLE
Limei Cheng
Favorite
Cheng, Lucy
Emory College
PII-069
-
EXTERNAL EVALUATION OF A POPULATION PHARMACOKINETICS MODEL OF CRITICALLY ILL PEDIATRIC PATIENTS RECEIVING MEROPENEM
Lucy Cheng
Favorite
Cheng, Yi-Hsien
U.S. Food and Drug Administration
PII-095
-
ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Yi-Hsien Cheng
Favorite
Chen, Yang
Daiichi Sankyo
PI-030
-
EFFECT OF VALEMETOSTAT ON THE PHARMACOKINETICS OF MIDAZOLAM AND DIGOXIN (CYP3A AND P-GP SUBSTRATES): A PHASE 1 DRUG-DRUG INTERACTION STUDY IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA.
Yang Chen
Favorite
Chen, Ying-Jung
Department of Pharmacy, National Taiwan University Hospital
LB-019
-
CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?
Ying-Jung Chen
Favorite
Chen, Yingxue
Ipsen
PI-078
-
PHARMACOKINETIC INTERACTION STUDIES OF COADMINISTRATION OF TAZEMETOSTAT WITH FLUCONAZOLE, REPAGLINIDE, OR OMEPRAZOLE IN PATIENTS WITH ADVANCED MALIGNANCIES.
Yingxue Chen
Favorite
Chen, Yizhe
Bristol Myers Squibb
PII-067
-
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE-2 TO HIGH-RISK MYELOFIBROSIS WITH OR WITHOUT PRIOR RUXOLITNIB EXPOSURE.
Yizhe Chen
Favorite
Cho, Yong-Soon
Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine
PII-062
-
COMPREHENSIVE PHARMACOKINETIC ANALYSIS OF ISONIAZID IN A LARGE COHORT OF TUBERCULOSIS PATIENTS: ADVANCED MODELING INCORPORATING EXTENSIVE CLINICAL COVARIATES.
Yong-Soon Cho
Favorite
Cho, Youngwoo
UChicago Medicine
OAI-001
-
YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Youngwoo Cho
Favorite
PT-010
-
YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Youngwoo Cho
Favorite
Chung, Taekyu
University of California San Francisco
PI-056
-
ALTERNATIVE DOSING GUIDELINES TO IMPROVE OUTCOMES IN MULTIDRUG-RESISTANT TUBERCULOSIS.
Taekyu Chung
Favorite
Collins, Keagan
Pfizer
PII-036
-
PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS
Keagan Collins
Favorite
PII-038
-
STRATEGIC CONSIDERATIONS FOR TUMOR DYNAMICS MODELING IN EARLY DEVELOPMENT: LEARNINGS FROM AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE
Keagan Collins
Favorite
